Trials / Completed
CompletedNCT00235014
A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)
A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,204 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The BENEDICT study is conducted to examine the effects of an ACE inhibitor, calcium channel blockade, a combination of these, and placebo, in the prevention of micro- and macro-albuminuria in Type 2 diabetic patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | trandolapril | 2 mg QD |
| DRUG | trandolapril/verapamil | 180/2 mg QD |
| DRUG | placebo | 1 tablet QD |
| DRUG | verapamil | SR 240 mg QD |
Timeline
- Start date
- 1997-03-01
- Primary completion
- 2006-01-01
- First posted
- 2005-10-10
- Last updated
- 2008-07-15
Source: ClinicalTrials.gov record NCT00235014. Inclusion in this directory is not an endorsement.